Biotech
TUSTIN, CA: Interim Data Shows 85% Overall Response Rate With 15% Complete Response Rate in HER2-Negative MBC; Final Data From Company's Phase II Pancreatic Cancer Trial Shows Promising Overall Survival Tren ...
TUSTIN, CA: Overall Survival Favors 3 mg/kg Bavituximab Plus Docetaxel Treatment Group Over Control Arm and Across Key Subgroups Analyzed; Data Support Global Phase III Registration Trial in Second-Line Non-Small ...
HALIFAX, NOVA SCOTIA: Immune responses consistent with those required for cancer vaccines to potentially impact disease progression; adds to growing excitement in field of cancer immunotherapy Poster is one of few selected ...
PARIS: Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma
...
SOUTH SAN FRANCISCO, CA: Responses Observed in Patients With Refractory Multiple Myeloma Treated With TH-302 Plus Dexamethasone; Responses Observed in Patients With Renal Cell Carcinoma and Gastrointestinal Stromal Tumors Tre ...
HALIFAX, NOVA SCOTIA: IMV's vaccine targets survivin peptides present on most Glioblastoma (Brain Cancer) cells Patients to receive DPX-Survivac in combination with immune modulating drug in effort to extend remission ...
